CytomX Therapeutics (NASDAQ:CTMX) says seven presentations
at ASCO provides evidence validating its approach to conditional
antibody activation and therapeutic target engagement with the Probody
platform.
Underpins advancement of four drug candidates into Phase 2 trials.
Includes presentation of clinical data for CX-2029, a Probody drug conjugate against CD71, a previously undruggable target.
Provides data updates for CX-2009 support Phase 2 investigations into breast cancer.
Reports favorable tolerability profile demonstrated for Anti-PD-L1 and Anti-CTLA-4 Probody therapeutics.
Shares slip 0.8% in premarket trading.
Conference call at 5:00 PM ET.
https://seekingalpha.com/news/3578652-cytomx-presents-on-probody-platform-asco
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.